Elastase, α1-Proteinase Inhibitor, and Interleukin-8 in Children and Young Adults with End-Stage Kidney Disease Undergoing Continuous Ambulatory Peritoneal Dialysis by Bożena Polańska et al.
ORIGINAL ARTICLE
Elastase, a1-Proteinase Inhibitor, and Interleukin-8 in Children
and Young Adults with End-Stage Kidney Disease Undergoing
Continuous Ambulatory Peritoneal Dialysis
Bo _zena Polan´ska • Daria Augustyniak • Irena Makulska •
Maria Niemczuk • Adam Jankowski • Danuta Zwolin´ska
Received: 28 March 2013 / Accepted: 14 November 2013 / Published online: 29 November 2013
 The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract Peritoneal dialysis is one of the main modality of
treatment in end-stage kidney diseases (ESKD) in children.
In our previous work in chronic kidney disease patients, in
pre-dialyzed period and on hemodialysis, the neutrophils
were highly activated. The aim of this study was to assess an
inflammatory condition and neutrophil activation in ESKD
patients undergoing continuous ambulatory peritoneal dial-
ysis (CAPD). Thirteen CAPD patients without infection,
both sexes, aged 2.5–24 years, and group of healthy subjects
(C) were studied. For comparative purposes the conserva-
tively treated (CT) group of ESKD patients was included.
Neutrophil elastase in complex with a1-proteinase inhibitor
(NE-a1PI; ELISA), a1-proteinase inhibitor (a1PI; radial
immunodiffusion) and interleukin-8 (IL-8; ELISA) were
measured in the blood samples from CAPD, CT, and C group
and in the peritoneal dialysate fluid (PDF) samples of
patients on CAPD. A significantly increased plasma NE-a1PI
levels (median 176.5 lg/L, range 85.2–373.2 lg/L;
p \ 0.00005), serum IL-8 (median 18.6 pg/mL, range
15.73–35.28 pg/mL; p \ 0.05), and slightly decreased
serum a1PI (median 1,540 mg/L, range 1,270–1,955;
p B 0.05) compared to the control groups were found. There
were no significant differences of analyzed parameters
between CAPD and CT patients. The concentration ratio of
NE-a1PI, a1PI and IL-8 in blood/PDF was 29.97, 8.24, and
4.48, respectively. There were significantly positive corre-
lations between serum and PDF concentration of a1PI and
IL-8 (r = 0.613, p \ 0.05; r = 0.59; p \ 0.005, respec-
tively). The results of our study demonstrate that neutrophils
are highly activated in non-infected CAPD patients. The
pivotal marker of this activation is NE-a1PI. It may con-
tribute to chronic inflammation and tissues injury.
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Abbreviations
CAKUT Congenital anomalies of kidney and urinary
tract
CAPD Continuous ambulatory peritoneal dialysis
CT Conservative treatment
CKD Chronic kidney disease
ESKD End-stage kidney disease
PDF Peritoneal dialysate fluid
B-CAPD Blood-CAPD
a1PIa1 a1-Proteinase inhibitor
NE-a1PI Neutrophil elastase complexed with
a1-proteinase inhibitor
IL-8 Interleukin-8
ELISA Enzyme-linked immunosorbent assay
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regarding their quantity, morphological or functional
changes (Santamaria et al. 2009; Wasik et al. 1997). As a
result, this leads to higher risk of developing inflammatory
conditions, such as peritonitis and catheter-related infection
(Stefaniak et al. 2002) as well as non-inflammatory com-
plications including cardiovascular disease, fibrosis,
impaired peritoneal ultrafiltration and an increase in mor-
tality (Litwin et al. 2001; Yamamoto et al. 2010).
Inflammation usually is associated with an overstimulation
of neutrophils and release of their proteolytic enzymes,
accompanied by the imbalance between cellular proteases
and their inhibitors, and the activation of pro-inflammatory
cytokines as well (Augustyniak et al. 2006; Korkmaz et al.
2005a; Lin and Huang 1994; Polan´ska et al. 2007). The
hallmarks of neutrophilic inflammation are neutrophil
elastase, a1-proteinase inhibitor (a1PI) and interleukin-8
(IL-8).
Free human neutrophilic elastase is regarded as one of
the most potent proteolytic enzymes. It plays an important
physiological function, being able to degrade foreign
phagocytized particles both intracellularly (Shapiro 2002)
and extracellularly (Papayannopoulos et al. 2010) and
facilitate cell migration through vascular walls (Kaynar
et al. 2008). One of the major and natural inhibitors of
elastase is a1PI (Korkmaz et al. 2005a), which protects the
surrounding tissues from enzyme-mediated destruction.
Neutrophil elastase, both in the free form and in enzy-
matically, inactive complex with a1PI, may be a good
indicator of the neutrophil activity (Polan´ska et al. 2004) as
well as the degree of inflammatory reactions in acute and
chronic diseases, including kidney disorders requiring
dialysis (Donovan et al. 1993; Polan´ska et al. 2006, 2010;
Shutov et al. 1999). IL-8 is the major chemotactic factor for
neutrophils which also participates in their activation
(Baggiolini and Clark-Lewis 1992) and degranulation
(Segura et al. 1998). It also plays a significant role in the
pathogenesis of inflammatory diseases (Baggiolini and
Clark-Lewis 1992), cardiovascular diseases (Apostolakis
et al. 2009) and fibrosis (Masunaga et al. 2003).
Although neutrophil elastase, a1PI and IL-8 play an
important role in modulation of inflammation, the number
of data referring to their significance in pediatrics patients
with chronic kidney disease (CKD) is highly limited.
Despite excessive data concerning the role of aforemen-
tioned mediators in kidney diseases analyzed separately,
little is known about interrelations between them in pedi-
atric patients in reference to renal replacement therapies.
The goal of our study was to evaluate the blood and peri-
toneal dialysate fluid (PDF) concentrations of NE-a1PI,
a1PI, and IL-8 in non-infected children and young adults




The study covered 13 children and young adults with
chronic and end-stage kidney disease (ESKD) on CAPD
patients, aged 2.5–24 years (12.1 ± 6.8 years,
mean ± SD), 7 females (54 %), and 6 males (46 %). The
patients were dialyzed from 0.5 to 10 years
(3.8 ± 3.6 years, mean ± SD) in the Department of
Pediatric Nephrology in Wroclaw, Poland. All patients
used conventional, low-glucose peritoneal dialysis solu-
tions. Clinical causes which led to a CAPD therapy are
shown in Table 1. All patients were clinically stable. In the
time of investigation there were no clinical and conven-
tional laboratory (C-reactive protein, erythrocyte
sedimentation rate, total leukocytes count) signs of infec-
tion. None of the patients enrolled in the study had
immunologic abnormalities. The patients with autoimmune
disease had complete clinical and biochemical remission.
Additionally, for comparative purposes the previously
published conservatively treated (CT) group was included
(Polan´ska et al. 2010). The CT group consisted of 13
patients, 6 females (46 %) and 7 males (54 %), aged
4–17 years (mean 12 ± 4.5 years), The causes of CKD in
the CT group were: chronic glomerular nephritis (n = 4),
hydronephrosis (n = 1), polycystic kidney disease (n = 4),
kidney hypoplasia (n = 1), chronic interstitial nephritis
(n = 1), and posterior urethral valves (n = 2). The control
(C) group consisted of healthy subjects, both sexes, without
chronic or recurrent diseases in anamnesis. Their results
were regarded as normal values for NE-a1PI (group C1,
n = 40, age range 1–16, mean 7 ± 4 years), for a1PI
(group C2, n = 29, age range 1–24, mean 10 ± 7 years),
and for IL-8 (group C3, n = 38, age range 1–24, mean
13.5 ± 7.5 years). None of the patients and controls
received drugs having potential anti-inflammatory
properties.
Material and Sampling Procedures
The material for investigation included peripheral venous
blood which was obtained along with the blood drawn for
routine laboratory tests from CAPD patients (B-CAPD),
CT and healthy subjects, and included PDF from the
abdominal cavity drawn simultaneously from CAPD
patients (PDF-CAPD). Samples from PDF were obtained
after 4 h dwell time. The blood samples, EDTA-treated
blood samples and PDF were centrifuged (3,000 rpm,
10 min) within 2 h after collection. The serum, plasma and
PDF were immediately divided into aliquots and stored at
-80 C until assayed.
240 Arch. Immunol. Ther. Exp. (2014) 62:239–245
123
This study was approved by the Research Ethics Com-
mittee of the Medical University of Wroclaw. The children
were enrolled for the study with parental agreement.
Informed consent was obtained from each patient’s parent
and adult patients.
Methods
Neutrophil elastase was determined by ELISA method in
plasma and in undiluted PDF as a complex with its natural
inhibitor, a1-proteinase using reagents manufactured by
Merck (Darmstadt, Germany). The serum and undiluted PDF
concentration of a1PI and IL-8/NAP-1 were investigated by
radial immunodiffusion method using the Binding Site kit
(Birmingham, UK), and ELISA kit of Bender MedSystems
(Vienna, Austria), respectively. The analyses were per-
formed according to the manufacturers’ recommendations.
The limits of detection for NE-a1PI and IL-8/NAP-1 were
\1.98 lg/L and \11 pg/mL, respectively. The coefficient
of variation of a1PI repeat measurements was\5 %.
Statistical Analysis
Statistical analysis was performed using the nonparametric
the Mann–Whitney U test for independent variables.
Spearman’s rank correlation coefficient was used to
investigate any relationship between the parameters. The
level of statistical significance was assumed to be p \ 0.05.
The analyses and illustrations were performed using Stat-
Soft software (Statistica 8).
Results
In all the analyzed samples of blood and PDFs investigated
markers were detectable (Tables 1, 2). Significantly higher
plasma NE-a1PI (p \ 0.00005) and serum IL-8 (p \ 0.05)












1 4 M Polycystic kidney disease
and hydronephrosis
4 259.08/3.1 2,060/370 12.83/2.64
2 5 M Polycystic kidney disease 4 28.49/8.67 2,000/237 16.08/2.52
3 16 F Chronic glomerulonephritis 10.5 176.5/2.3 1,540/207 18.6/27.85
4 24 M Vesicoureteral reflux 10 537.5/9.9 169/166 124.15/14.73
5 10 M Vesicoureteral reflux 1 85.2/0.8 1,430/201 32.43/6.76
6 24 F Rheumatoid arthritis and
amyloidosis
8 131.6/11.9 1,320/148 144.36/89.6
7 15 F Neurogenic bladder 3.5 373.2/1.45 1,540/178 14.75/3.19
8 2.5 F Congenital nephrotic syndrome 1.5 422.3/0.2 932/178 35.28/2.88
9 12 F Polyvasculitis 0.5 76.5/18.2 –/166 16.03/3.25
10 11 F Hydronephrosis and neurogenic
bladder
0.5 125.5/– 1,120/– 25.83/–
11 12 F Hemolytic-uremic syndrome 0.5 73.4/23.4 1,940/172 15.73/4.15
12 7 M Primary hyperoxaluria 5 198.4/1.7 2,130/196 84.44/5.5
13 15 M Vesicoureteral reflux 0.5 427.89/25 1,820/207 11.45/–
F female, M male, PDF peritoneal dialysate fluid, – not tested
Table 2 Blood concentrations of the studied inflammatory markers
in the CAPD, CT patients and healthy controls

























C3 – – 13.49
(7.94–28.14)
Statistics was performed with Mann–Whitney U test, the results are
presented as median value and interquartile range (25–75 %). Com-
parison B-CAPD and CT (for NE-a1PI, a1PI, and IL-8): not
significant
B-CAPD blood of CAPD patients, PDF-CAPD peritoneal dialysate
fluid of CAPD patients, C1, C2, C3 healthy subjects for NE-a1PI,
a1PI and IL-8, respectively
Comparison with normal value: * p \ 0.00005, ** p B 0.05,
# p \ 0.05,  p \ 0.000001
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levels were observed in CAPD patients in comparison to
healthy subjects. In 4/13 cases (31 %) plasma NE-a1PI
levels were within the normal range (60.78 ± 54.20 lg/L;
mean ± 2SD) and in 5/13 (38 %) cases levels were above
200 lg/L. The median values of a1PI was slightly, but
significantly (p B 0.05) below the accepted norms. In the
majority of samples [10/12 (83 %)] concentrations of a1PI
were within the normal limits (1,862.01 ± 825.8 mg/L;
mean ± 2SD). Particularly low concentrations of a1PI we
found in the blood of two patients who had simultaneously
elevated levels of NE-a1PI [first patient with vesicoureteral
reflux (a1PI 169 mg/L, NE-a1PI 537.5 lg/L) and second
with congenital nephrotic syndrome (a1PI 932 mg/L,
NE-a1PI 422.3 lg/L)]. The analysis of a1PI in CAPD group
depleted of at least one mentioned serum samples versus
controls abolishes the indicated above significance. Serum
IL-8 was above the reference range (17.41 ± 26.18 pg/mL,
mean ± 2SD) in 3/13 (23 %) patients. One of them was
the same person who had simultaneously elevated con-
centration of NE-a1PI and a1PI (with vesicoureteral reflux,
IL-8 124.15 pg/mL, NE-a1PI 537.5 lg/L, a1PI 169 mg/L).
There were no significant differences between B-CAPD
and CT patients in reference to all three measured indica-
tors (Table 2). The differences between CT patients and
controls have been published previously (Polan´ska et al.
2010).
The B-CAPD levels of NE-a1PI were 30-fold higher,
a1PI, eightfold higher whereas IL-8 only 4.5-fold higher
comparing to their counterparts in PDF-CAPD. All tested
inflammatory markers were in much lower concentrations
in the PDF-CAPD compared to their levels accepted as the
normative values in peripheral blood (NE-a1PI and a1PI
about 10 times, IL-8 3.5 times lower). There were signifi-
cant positive correlation between serum and PDF
concentration of a1PI (r = 0.613, p \ 0.05) and IL-8
(r = 0.59, p \ 0.005), see Fig. 1. There were no correla-
tions between the blood concentration of NE-a1PI, a1PI
and IL-8 and between plasma and PDF concentrations of
NE-a1PI. No statistically significant differences in con-
centrations of NE-a1PI, a1PI and IL-8 between the blood,
PDF and duration of CAPD therapy were found.
Considering the potential influence of congenital
anomalies of kidney and urinary tract (CAKUT) in CAPD
patients on tested parameters, we did not find any signifi-
cant differences between CAKUT group (Table 1: no. 1, 2,
4, 5, 10, 13) and that with other underlying diseases.
Discussion
In long-therapy of CAPD patients with ESKD, the com-
petent systemic and local, peritoneal immune defense
mechanisms are very important. The results of our previous
data clearly showed the high activity of neutrophils in
young ESKD patients on hemodialysotherapy as well as in
conservatively treated patients. It has been confirmed by
considerable increase in circulatory level of NE-a1PI
(Polan´ska et al. 2010). The results of our present study
indicate that also in CAPD patients we found elevated
levels of NE-a1PI in plasma. At the same time the con-
centration of NE-a1PI in the PDF were approximately
tenfold lower in comparison to normal plasma levels,
suggesting higher activity of neutrophils in peripheral
blood than in the peritoneal cavity.
Due to the variety of relationships and interactions
between the cells and their metabolites it is difficult to
clearly identify the causes and the clinical consequences of
increase activation of neutrophils in blood. The results of
our study revealed that CAPD patients have a tendency to
possess higher values of NE-a1PI and IL-8 than CT ones as
compared to normal. We can only speculate that this is
presumably in part a result of the body response to stim-
ulating action of both the not fully removed circulated
uremic toxins, invasiveness of the peritoneal dialysis pro-
cedure, inbiocompatibility dialysis solutions and IL-8
activities. Furthermore, it may be also connected with the
property of neutrophil elastase in complex with a1PI to
serve as a neutrophil chemoattractant (Banda et al. 1988).
We can also assume that in the peritoneal cavity of our
Fig. 1 Correlations between serum and PDF a1PI concentrations
(a r = 0.613, p \ 0.05) and between serum and PDF IL-8 (b r = 0.59,
p \ 0.005) concentrations in patient with ESKD on CAPD
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patients there was no acute inflammation which can over-
stimulate neutrophils. The concentration of NE-a1PI and
free elastase activity determined in the peritoneal cavity
has already been studied in patients without peritonitis,
showing the reduction of both form of enzyme (Donovan
et al. 1993). Conversely, in peritonitis a common compli-
cation of CAPD in children, elevated levels of elastase both
in plasma and dialysate fluid were observed (Shutov et al.
1999).
The consequences of observed NE-a1PI increase in
pediatric patients for whom peritoneal dialysis is often a
method of choice (especially in smaller children) may be
diverse. Firstly, as the dynamic changes in the concentration
of free neutrophil elastase or NE-a1PI in body fluids are very
sensitive, its excessive amount may have significant
importance for the preservation of homeostasis. Secondly,
when elastase is released from overactivated neutrophils or
after their apoptosis, unbounded neutrophil elastase can
destroy extracellular matrix, basement membranes (Chua
and Laurent 2006), and promote microvascular injury
(Carden et al. 1998). This proteolytic feature of enzyme may
prevent from fibrosis development, one of the most serious
side effects of the long-term peritoneal dialysis (Yamamoto
et al. 2010). On the other hand, however, neutrophil elastase
paradoxically participates in excessive extracellular matrix
deposition that leads to pulmonary fibrosis (Yamanouchi
et al. 1998). Furthermore, neutrophil elastase inactivates
complement components C3 and C5a, immunoglobulins,
protease inhibitors, clotting factors and cell adhesion mol-
ecules that have a direct impact on the course of the
inflammatory reactions (Lee and Downey 2001). All afore-
mentioned autoaggressive properties of neutrophil elastase
may contribute to the increase of the pathological remodel-
ing of tissues in CKD patients. Thus, even a small amount of
free neutrophil elastase present in the peritoneal cavity of our
patients may support microinflammation of peritoneal
membrane and ultrafiltration failure (Andreoli et al. 1994;
Bos et al. 1991; Donovan et al. 1993). The reduced quantity/
activity of neutrophil elastase may result also in neutrophil-
related endothelial cell injury and increase vasculature per-
meability (Kaynar et al. 2008).
Neutrophil elastase activity is fully controlled by a1PI
and other inhibitors as long as they are present in excess. It
is worth to add that about 12 % of neutrophil elastase
content in primary neutrophil granules is mobilized to the
cell membrane where neutrophil elastase is resistant to
inhibitors and remains catalytically active (Korkmaz et al.
2005b; Owen et al. 1995). The results of our study have
shown that elevated concentrations of NE-a1PI were not
accompanied by the a1PI increase in peripheral blood in
both CKD groups. We suspect that this may be only an
apparent shortage as a result of the rapid consumption of
inhibitor molecules by excessively released neutrophil
elastase and subsequent elimination of NE-a1PI complexes
(Korkmaz et al. 2005a). Because a1PI is considered as a
positive marker of acute inflammatory reaction, its low
quantity probably reflects the lack of such a response in our
patients. Another explanation may be the proteolytic deg-
radation of a1PI by myeloperoxidase (Honda et al. 2009) or
neutrophil elastase (Cantin et al. 1989), indirectly con-
firmed by the lack of significant correlations between
NE-a1PI and a1PI both in the blood and PDF CAPD
samples. Finally, a1PI inactivation may be the result of
excessive oxidative stress which occurs in patients on
dialysis (Zwolin´ska et al. 2009) followed by the release of
free reactive oxygen species (Carp and Janoff 1980).
Identified relatively low concentrations of IL-8 in the
serum of CAPD patients, although significantly higher when
compared to healthy control (p = 0.036) indicate rather a
chronic inflammation or microinflammation than the acute
condition. This can be however a real risk for cardiovascular
complications (Apostolakis et al. 2009). It is worth noting
that in our patients, without clinical manifestations of peri-
tonitis, it was the smallest differences in the concentrations
of IL-8 between the serum and the PDF in comparison to
NE-a1PI and a1PI. This may be partly the result of the easier
compensation of pro-inflammatory cytokines by anti-
inflammatory cytokines observed in children (Pereira 1995)
or suppressive action of free radicals on the production of
IL-8 (DeForge et al. 1992). In accordance with other data we
speculate therefore that the source of IL-8 found in the PDF
samples may be rather cytokine-activated peritoneal mac-
rophages or fibroblasts (Lin and Huang 1994; Witowski et al.
2001) than neutrophils.
The lack of significant correlation found between IL-8
and NE-a1PI in the blood and PDF can provide that neu-
trophil degranulation followed by the release of elastase
was also influenced by other factors, such as (not deter-
mined in this work) the components of complement,
leukotrienes, and tumor necrosis factor a. Positive corre-
lation between serum and PDF IL-8 and a1PI
concentration, found in investigated samples, may be partly
the consequence of the chronic or microinflammation
presence in long-term dialysed uraemic patients, even
without clinical signs. As demonstrated by Bergin et al.
(2010) a1PI may play also an anti-inflammatory role by
inhibiting neutrophil chemotaxis. It forms a complex with
IL-8, and controls the binding of IL-8 with CXCR1 (neu-
trophil chemokine receptor). The interaction between
neutrophil elastase, inhibitor a1-proteinase and IL-8 con-
tributes to the perpetuating circle that facilitates the
recruitment of inflammatory cells and amplifies the neu-
trophil-associated tissue destruction.
There are some limitations to the present study, thus all
conclusions must be assessed carefully. First, issue is the
low number of pediatric patients, reflecting the general
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difficulty in performing clinical studies in this population.
Secondly, few of our patients have underlying inflamma-
tory diseases which might affect the evaluated parameters.
Thirdly, we did not evaluate the functional activities of the
study parameters or other multidirectional cellular and
molecular interactions influencing them. We did not per-
form also laboratory data excluding the primary a1PI
deficiency. Finally, because we performed a clinical study,
our conclusions are based rather on associations and cannot
prove causality.
In conclusion, the results of our study due to the fact of
increased concentration of NE-a1PI in peripheral blood and
their presence in PDF demonstrate that neutrophils are
highly active in non-infected CAPD patients. The investi-
gation of the innate immunity components might show new
indices on pathogenesis, identify novel therapeutic targets
for treatment, and prevent from many complications
improving the life quality of these patients.
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